Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;17(4):453-455.
doi: 10.14802/jmd.24114. Epub 2024 Jun 28.

Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report

Toshiki Tezuka  1   2 , Tomonori Nukariya  1   2 , Yuta Kizuka  1 , Shohei Okusa  1   2 , Ryotaro Okochi  1   2 , Yuto Sakai  1   2 , Yoshihiro Nihei  1   2 , Jin Nakahara  1   2 , Morinobu Seki  1   2
Affiliations

Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report

Toshiki Tezuka et al. J Mov Disord. 2024 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no financial conflicts of interest.

Figures

Figure 1.
Figure 1.
The clinical course of Parkinson’s disease with the adjustment of foslevodopa/foscarbidopa and concomitant antiparkinsonism medications. Clinical course showing the degree of motor symptoms and psychosis, plasma levodopa concentrations (ng/mL), infusion rates of foslevodopa/foscarbidopa (mL/hr), and concomitant medications. Regarding foslevodopa/foscarbidopa, the solid line indicates the standard infusion rate, and the dotted line indicates the lower alternative infusion rate. AMT, amantadine; CD, carbidopa; CSCI, continuous subcutaneous infusion; IST, istradefylline; LD, levodopa; OPC, opicapone; RSG, rasagiline; ZNS, zonisamide.
See this image and copyright information in PMC

References

    1. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323:548–560. - PubMed
    1. Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62:1–8. - PubMed
    1. Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson’s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther. 2023;12:1937–1958. - PMC - PubMed
    1. Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: considerations for initiation and maintenance. Clin Park Relat Disord. 2024;10:100239. - PMC - PubMed
    1. Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21:1099–1109. - PubMed

LinkOut - more resources